Rezolute, Inc. Faces Severe Share Price Drop After Trial Failure: Investigations Underway

Rezolute, Inc. Faces a Crisis: Share Price Plummets 90%

On December 11, 2025, investors in Rezolute, Inc. (NASDAQ: RZLT) experienced a shocking drop in share value, plummeting by up to 90% during intraday trading. This alarming decline followed the announcement of the failed Phase 3 trial results for their drug, ersodetug, which was aimed at treating hypoglycemia resulting from hyperinsulinism (HI).

The company's mission had been to provide effective treatment options for those suffering from HI, and until recently, Rezolute had been optimistic about its potential. With statements highlighting the drug's promise, company officials had maintained that ersodetug could significantly reduce hypoglycemic events and enhance the quality of life for affected individuals. As recently as mid-November, leadership asserted that the Phase 3 study was set to deliver robust evidence of efficacy and safety for the drug.

However, disappointment struck suddenly when Rezolute reported that the trial did not meet its primary endpoint, leading to an unexpected and significant market backlash. According to their announcement, the results indicated that the decrease in hypoglycemia events was not statistically meaningful compared to the placebo, and the secondary endpointwhich evaluated changes in daily hypoglycemia averagesalso failed to meet expectations.

This reversal generated an immediate market response, causing the share price to plummet dramatically. Analysts reacted swiftly as well, with one downgrading the stock from outperform to neutral and slashing the price target from $12 to just $1. Such drastic analyst actions reflect deep concerns about the company’s future and the integrity of their earlier claims about ersodetug.

In light of the substantial losses sustained by investors, the Hagens Berman law firm has initiated an investigation to determine if Rezolute misled its stakeholders regarding the drug's development and market potential. According to Reed Kathrein, the leading partner in the case, they aim to uncover whether Rezolute.com was transparent and accurate in its communication surrounding ersodetug’s efficacy.

In the wake of these developments, Hagens Berman is actively encouraging any investors who encountered significant financial loss due to these circumstances to come forward and report their experiences. Furthermore, the firm is particularly interested in hearing from individuals who may possess insider knowledge that could assist in their investigation. The firm has suggested that anyone identified as a whistleblower could potentially benefit financially if their information leads to private or regulatory recoveries.

As investigations continue, the focus remains on the viability of Rezolute, Inc. and the future of its operations in light of this dramatic public fallout. Investors, analysts, and market watchers alike will be keeping a close eye on developments at Rezolute in the coming weeks as the implications of this failed trial unfold. The company’s next steps are pivotal for restoring confidence among shareholders and navigating forward in a challenging and unpredictable market environment.

If you are a Rezolute investor and have incurred financial losses, consider engaging with the legal team at Hagens Berman to understand your options. Transparency, accountability, and protecting investor rights remain critical as this situation develops.

For additional information and ongoing updates related to this scenario, visit the Hagens Berman website or get in touch with the firm directly with any pertinent information that could aid in their investigation.